Informing selection of drugs for COVID-19 treatment through adverse events analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Informing selection of drugs for COVID-19 treatment through adverse events analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-07
DOI
10.1038/s41598-021-93500-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
- (2020) Hussin A. Rothan et al. JOURNAL OF AUTOIMMUNITY
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
- (2020) Eli S. Rosenberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
- (2020) Kenichiro Sato et al. BioScience Trends
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
- (2020) Jianjun Gao et al. BioScience Trends
- Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
- (2020) Cynthia Liu et al. ACS Central Science
- COVID-19 and the Drug Repurposing Tsunami
- (2020) Hermann A.M. Mucke ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme
- (2020) Shilpa Chatterjee et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
- (2020) Andrea Cortegiani et al. JOURNAL OF CRITICAL CARE
- No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
- (2020) J.M. Molina et al. MEDECINE ET MALADIES INFECTIEUSES
- Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
- (2020) Markus Hoffmann et al. NATURE
- Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- (2020) Pauline Maisonnasse et al. NATURE
- Immune-mediated approaches against COVID-19
- (2020) Helena F. Florindo et al. Nature Nanotechnology
- Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs
- (2020) Zhe Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
- (2019) Leihong Wu et al. BMC BIOINFORMATICS
- DrugBank 5.0: a major update to the DrugBank database for 2018
- (2017) David S Wishart et al. NUCLEIC ACIDS RESEARCH
- Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events
- (2016) Yue Yu et al. Scientific Reports
- BioPortal: ontologies and integrated data resources at the click of a mouse
- (2009) N. F. Noy et al. NUCLEIC ACIDS RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started